[go: up one dir, main page]

PE20050948A1 - CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV - Google Patents

CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV

Info

Publication number
PE20050948A1
PE20050948A1 PE2004000875A PE2004000875A PE20050948A1 PE 20050948 A1 PE20050948 A1 PE 20050948A1 PE 2004000875 A PE2004000875 A PE 2004000875A PE 2004000875 A PE2004000875 A PE 2004000875A PE 20050948 A1 PE20050948 A1 PE 20050948A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
carbamoil
inhibitors
trans
amino
Prior art date
Application number
PE2004000875A
Other languages
Spanish (es)
Inventor
Kota Asahina
Yuki Kitao
Satoru Kobayashi
Kenichi Matsui
Masaki Yamashita
Hisashi Shinkai
Toshio Taniguchi
Kazuhiro Tsutsumi
Tomohiro Oda
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34317220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20050948A1 publication Critical patent/PE20050948A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE CARBAMOIL-AMINA DE FORMULA (I), EN DONDE R1 ES H, ALQUILO(C1-C6), CICLOALQUILO (C3-C12) OPCIONALMENTE SUSTITUIDOS, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), OPCIONALMENTE SUSTITUIDOS; R3 ES CICLOALQUILO(C3-C12) OPCIONALMENTE SUSTITUIDO; R4 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C12), HETEROCICLO SATURADO DE 3 A 7 MIEMBROS, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: ACIDO 2-{TRANS-4-[(S)-AMINO-(N-CICLOBUTIL-N-METILACARBAMOIL)METIL]CICLOHEXILMETOXIMETIL}BENZOICO, ACIDO 3-{TRANS-4-[(S)-AMINO-(N-CICLOBUTIL-N-METIL-CARBAMOIL)METIL]CICLOHEXILMETOXIMETIL-5-DIMETILAMINOBENZOICO, (2-METANOSULFONIL)FENILAMIDA DE ACIDO TRANS 4-[(S)-AMINO-(N-CICLOBUTIL-N-METILCARBAMOIL)METIL]CICLOHEXANOCARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA DIPEPTIDIL PEPTIDASA DPP-IV, POR LO QUE SON UTILES PARA EL TRATAMIENTO DE LA DIABETES TIPO II, OBESIDAD O SIMILARESREFERS TO COMPOUNDS DERIVED FROM CARBAMOIL-AMINE OF FORMULA (I), WHERE R1 IS H, ALKYL (C1-C6), OPTIONALLY SUBSTITUTED CYCLOALKYL (C3-C12), AMONG OTHERS; R2 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C12), OPTIONALLY SUBSTITUTED; R3 IS CYCLOALKYL (C3-C12) OPTIONALLY SUBSTITUTED; R4 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C12), SATURATED HETEROCYCLE OF 3 TO 7 MEMBERS, OPTIONALLY REPLACED. PREFERRED COMPOUNDS ARE: 2- {TRANS-4 - [(S) -AMINO- (N-CYCLOBUTYL-N-METHYLACARBAMOYL) METHYL] CYCLOHEXYLMETOXIMETHYL} BENZOIC ACID, 3- {TRANS-4 - [(S) -AMINO- ( N-CYCLOBUTYL-N-METHYL-CARBAMOYL) METHYL] CYCLOHEXYLMETOXIMETHYL-5-DIMETHYLAMINOBENZOIC, (2-METHANOSULFONYL) TRANS 4 ACID PHENYLAMIDE - [(S) -AMINO- (N-CYCLOBUTILBUTYL-N-METHYLOCAR) HEXYLBUTYL-N-METHYLOCARYL OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OF THE DIPEPTIDIL PEPTIDASE DPP-IV ENZYME, SO THEY ARE USEFUL FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, OR SIMILAR

PE2004000875A 2003-09-09 2004-09-09 CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV PE20050948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003317407 2003-09-09
JP2003395879 2003-11-26
JP2004114685 2004-04-08

Publications (1)

Publication Number Publication Date
PE20050948A1 true PE20050948A1 (en) 2005-12-16

Family

ID=34317220

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000875A PE20050948A1 (en) 2003-09-09 2004-09-09 CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV

Country Status (4)

Country Link
AR (1) AR046330A1 (en)
PE (1) PE20050948A1 (en)
TW (1) TW200530157A (en)
WO (1) WO2005025554A2 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20033521A3 (en) 2001-06-27 2004-05-12 Smithklineábeechamácorporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
CN101166527A (en) * 2005-04-27 2008-04-23 艾尼纳制药公司 Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
JP2009533393A (en) 2006-04-12 2009-09-17 プロビオドルグ エージー Enzyme inhibitor
WO2008020026A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for treating dermatitis
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
DK2091948T3 (en) 2006-11-30 2012-07-23 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US8957219B2 (en) 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
MX2011006524A (en) 2008-12-19 2011-08-17 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs.
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
KR20120083905A (en) * 2009-10-09 2012-07-26 자프겐 코포레이션 Sulphone compounds for use in the treatment of obesity
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
EA022420B1 (en) 2010-03-10 2015-12-30 Пробиодруг Аг Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US20130023494A1 (en) 2010-04-06 2013-01-24 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
CN103119057B (en) 2010-06-24 2016-06-15 印第安纳大学研究及科技有限公司 Insulin prodrug based on amide
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
CN103221410B (en) 2010-09-22 2017-09-15 艾尼纳制药公司 GPR119 receptor modulators and treatment of disorders associated therewith
KR20140006888A (en) 2011-01-26 2014-01-16 자프겐 인크. Tetrazole compounds and methods of making and using same
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
JP5941981B2 (en) 2011-05-06 2016-06-29 ザフゲン，インコーポレイテッド Tricyclic sulfonamide compounds and methods for their production and use
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9440943B2 (en) 2012-01-18 2016-09-13 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
MX2014008706A (en) 2012-01-18 2015-03-05 Zafgen Inc Tricyclic sulfonamide compounds and methods of making and using same.
KR20150080614A (en) 2012-11-05 2015-07-09 자프겐 인크. Tricyclic compounds for use in the treatment and/or control of obesity
EA028367B1 (en) 2012-11-05 2017-11-30 Зафджен, Инк. Methods of treating liver diseases
CA2890342A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds and methods of making and using same
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
BR112017008809A2 (en) 2014-11-05 2017-12-19 Flexus Biosciences Inc immunoregulatory agents
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2899852T3 (en) 2014-12-17 2022-03-15 Pimco 2664 Ltd N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(-4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
UA126268C2 (en) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. Methods of treating conditions related to the s1p1 receptor
BR112017019170A2 (en) 2015-03-09 2018-07-10 Intekrin Therapeutics, Inc. Methods for treating non-alcoholic fatty liver disease and / or lipodystrophy
MA42807A (en) 2015-06-22 2018-07-25 Arena Pharm Inc SALT L-ARGININE CRYSTALLINE ACID (R) -2- (7- (4-CYCLOPENTYL-3- (TRIFLUOROMETHYL) BENZYLOXY) -1,2,3,4-TETRAHYDROCYCLO-PENTA [B] INDOL-3-YL) ACETIC (COMPOUND 1) FOR USE IN CONDITIONS ASSOCIATED WITH THE S1P1 RECEIVER
ES2986023T3 (en) 2016-04-04 2025-01-27 Res Triangle Inst Neuropeptide s receptor (npsr) agonists
MA47504A (en) 2017-02-16 2019-12-25 Arena Pharm Inc COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
KR102859841B1 (en) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. Treatment of conditions associated with the S1P1 receptor
US10683267B1 (en) * 2019-11-21 2020-06-16 King Abdulaziz University Antidiabetic compounds
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
WO2025131062A1 (en) * 2023-12-21 2025-06-26 江苏恒瑞医药股份有限公司 Olefin compound, preparation method therefor and use thereof in medicine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
SE9701245D0 (en) * 1997-04-04 1997-04-04 Bjoern Classon antivirals
CO5150173A1 (en) * 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
EP1434769A2 (en) * 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
CA2468192A1 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes

Also Published As

Publication number Publication date
TW200530157A (en) 2005-09-16
WO2005025554A3 (en) 2005-07-28
WO2005025554A2 (en) 2005-03-24
AR046330A1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
PE20050948A1 (en) CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
ECSP088765A (en) AMINOTETRAHYDROPIRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
PE20060777A1 (en) INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
PE20060921A1 (en) PROCEDURE TO PREPARE CHIRAL 8- (3-AMINO-PIPERIDIN-1-IL) -XANTHINES
PE20081836A1 (en) PIPERIDINE DERIVATIVES AS INHIBITORS OF FATTY ACID SYNTHASE
PE20070367A1 (en) SPIROPIPERIDINE COMPOUNDS AS INHIBITORS OF THE BETA SECRETASE ENZYME
PE20081545A1 (en) SULFONAMIDE DERIVATIVES AS SYNTHASE FATTY ACID INHIBITORS
PE20070136A1 (en) COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1
NI201100081A (en) AMINOTETRAHYDROPYRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASE - IV FOR THE TREATMENT OR PREVENTION OF DIABETES.
AR062797A1 (en) PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS.
PE20050012A1 (en) BENZOPYRANE COMPOUNDS AS CYCLOOXYGENASE-2 INHIBITORS
AR053415A1 (en) DIPEPTIDIL PEPTIDASA IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF COMPOUNDS AND COMPOSITION
PE20091834A1 (en) 2-IMINO-3-METHYLPYRROLOOPYRIMIDINONE THIOPHENYL-SUBSTITUTED COMPOUNDS AS BACE-1 INHIBITORS AND COMPOSITIONS CONTAINING THEM
PE20071326A1 (en) VIRAL POLYMERASE INHIBITORS
PE20060316A1 (en) PROLIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS
PE20081504A1 (en) REPLACED BICYCLOCARBOXIAMIDE COMPOUNDS
PE20090880A1 (en) HETEROCYCLIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
PE20081487A1 (en) NICOTINAMIDE DERIVATIVES AS INHIBITORS OF 11ßHSD1
PE20040898A1 (en) NEW COMPOUNDS DERIVED FROM PYRIMIDINE
PE20050864A1 (en) HETEROCICLYLAMINE COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1
PE20130311A1 (en) COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING TRACK
GT200800242A (en) BICYCLE DERIVATIVES AS CETP INHIBITORS
PE20142282A1 (en) NEW ARYL-QUINOLINE DERIVATIVES
PE20080364A1 (en) SUBSTITUTED BIPHENYLCARBOXYL ACID AND ITS DERIVATIVES AS MODULATORS OF THE ACTIVITY OF THE GAMMA-SECRETASE
PE20080702A1 (en) PROLINAMIDES SUBSTITUTED AS INHIBITORS OF FACTOR Xa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal